Abstract: This invention is directed to the employment of a specific diuretic, methyclothiazide, in minimal dosage of 2.5 to 5.0 mg. per 48 hour period; preferably every other morning in conjunction with a daily dosage of an antibiotic tetracycline, in minimal dosage of 250 mg.daily; and, the unique method of treatment and administering these compounds.Acne vulgaris is divided into grades. This discovery is for the unique treatment and control of acne vulgaris grades 1, 11/2 and usually 2.

Abstract: Heterocyclic compounds which are inhibitors of histamine activity, in particular, inhibitors of H-2 histamine receptors. A specific compound of this invention is 2-[2-(4-methyl-5-imidazolylmethylthio)ethylamino]-4-pyrimidone.

Abstract: Compounds of the formula ##STR1## WHEREIN A is a linking group, X is an O--CO-- or --SO.sub.2 -- group and n is at least 2, are prepared from the corresponding N',N'-disubstituted hydrazides by quaternization and treatment with alkali or reaction with an alkylene epoxide or from the corresponding compound wherein n = 1 and A is a polymerizable group by polymerization. The compounds are unstable to heat and may be used as cross-linking agents for polymers or as chain-extending agents, bonding agents or adhesives.

Abstract: An improvement in infusion solutions for parenteral solutions containing normally water-insoluble lipids and/or essential fatty components is disclosed. A minor amount sufficient to solubilize the said normally water-insoluble lipids and fatty components of a solubilizing mixture of ethanol and at least one member selected from the group consisting of propanediol, butane diol and hydroxy-substituted cholanic acid derivatives is mixed with the infusion solution to obtain a clear, pyrogen-free solution.

Abstract: A topical ointment composition is provided which includes a mixture of non-systemic bases comprising calcium carbonate, magnesium hydroxide, and aluminum hydroxide. The composition also includes an anhydrous lanolin base carrier material and a hydrophilic ointment base carrier material, and the ointment composition is effective to essentially adjust the acid-base balance at the area of topical application to a point which corresponds with normal healthy body tissue. The composition may further include a compound having pharmaceutically acceptable anesthetic properties. In addition to the topical ointment composition, a method is provided for treating skin injuries involving inflammation or destruction of tissue, such as decubitus ulcers, varicose ulcers and burns, which method involves preparing the above noted composition and applying it to the affected area.

Abstract: A mucolytic process is disclosed which comprises contacting N-(2-hydroxyethyl)mercaptoacetamidobenzamides or mercaptoacylamidobenzoic acids, mercaptoacetylsulfanilic acids and alkanoylthio derivatives thereof with mucus. Illustrative of compounds useful in the mucolytic process of the present invention are 4-(2-mercaptoacetamido)benzoic acid and N-(2-mercaptoacetyl)sulfanilic acid.

Abstract: Nitro-indane-diones, their production, and pharmaceutical compositions and their administration in forms suitable for the prophylaxis of asthma, hayfever and rhinitis in amounts effective for oral, parenteral and insufflation administration for such forms. The compounds are nitro-indane-diones of the formula: ##STR1## wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 have certain designated meanings, obtained by nitration of a parent un-nitrated compound and wherein ring A contains 1 or 2 double bonds.

Abstract: Disclosed are novel substituted pyridinyloxy(thio)phenyl -acetamides, -ureas and urea derivatives, N-oxide derivatives thereof, and certain novel intermediates therefore. The compounds of the instant invention are useful as herbicides and can be formulated to provide herbicidal compositions.

Abstract: Phenoxypropanolamine derivatives are prepared. These compounds have .beta.-adrenergic stimulant activity particularly as selective bronchodilators.

Abstract: A compound of the formula ##STR1## or a salt thereof, OR OF THE FORMULA ##STR2## OR A SALT THEREOF, WHEREINR.sup.1 and R.sup.2 are the same or different and each is hydrogen, lower alkyl, cycloalkyl of 4 to 7 carbon atoms, aryl of 6 to 14 carbon atoms, or aralkyl of up to 18 carbon atoms wherein the alkyl moiety contains up to 6 carbon atoms; andn is 3, 4 or 5;Is produced by hydrolyzing a compound of the formula ##STR3## wherein R.sup.1, R.sup.2 and n are as above defined, andX is halogen;A compound of the formula ##STR4## or a hydrohalide thereof, wherein R.sup.1, R.sup.2, n and X are as above defined; orA compound of the formula ##STR5## wherein R.sup.1, R.sup.2, n and X are as above defined;In the presence of a base at a temperature of from about 20.degree. to about 180.degree. C.The compounds produced are valuable intermediates from which cyclic amino acids and .alpha.,.omega.-diaminocarboxylic acids are obtained.

Abstract: A method of treating ophthalmological disorders is disclosed. The method comprises the oral administration from one to four times a day of a composition comprising:A. from 200 to 1,000 mg of a compound selected from the group consisting of cystine and cysteineB. from 50 to 300 mg of pyridoxine in the form of a base or a salt.

Abstract: Cholinestrase reactivators are administered to treat the pain of tic douloureux.

Abstract: A method of improving the endogenous production of prostaglandins by a mammal is disclosed, which comprises administering to the mammal an effective amount of certain 1-pyridylalkyl-3-phenylureas. Disclosed also are novel substituted 1-pyridylalkyl-3-phenylureas and therapeutic compositions thereof which are useful in carrying out the method of the invention.Disclosed also are methods of treating mammals for clinical conditions responsive to prostaglandins, such as, for example, male infertility, epidermal injuries, atonic uterine bleeding, thromboembolic disease and like clinical conditions.

Abstract: 1-Amino-3-(4- or 5-substituted thiazol-2-oxy)-2-propanol and/or substituted amino derivatives thereof; 3-(4- or 5-substituted thiazol-2-oxy)-1,2-epoxypropane and 5-(4- or 5-substituted thiazol-2-oxymethylene)-oxazolidine and/or N- and/or 2-substituted oxazolidine derivatives thereof, are methods of making such compounds. The compounds are characterized by an aminocarbonyl or carbonylamino type substituent at the 5- or 4-position on the thiazole ring. The above 1-amino-3-(4- or 5-substituted thiazol-2-oxy)-2-propanol and derivatives exhibit cardiovascular activity and are useful in the treatment of abnormal heart conditions in mammals. The 3-(4- or 5-substituted thiazol-2-oxy)-1,2-epoxypropanes are useful as intermediates for the aforementioned cardiovascular agents.

Abstract: Ethers and esters of 1-hydroxy-2-(1,1-difluoroalkyl)-1H-imidazo(4,5-b)pyridine compounds, useful as herbicides.

Abstract: Pharmaceutical compositions and methods of inhibiting H-1 and H-2 histamine receptors by administering an antihistamine and an H-2 histamine receptor inhibitor. Exemplary of the antihistamine in the compositions and methods of this invention is mepyramine and exemplary of the H-2 histamine receptor inhibitor is N-cyano-N'-methyl-N"-[2-((4-methyl-5-imidazolyl)-methylthio)ethyl]guanidin e.

Abstract: Pharmaceutical dosage unit compositions containing as an active ingredient a compound of the formula ##STR1## wherein R.sub.1 is hydrogen or lower alkyl, R.sub.2, R.sub.4 and R.sub.5, which may be identical to or different from each other, are each hydrogen, lower alkyl, hydroxyl, lower alkoxy, acyloxy, halogen, nitro or --SO.sub.3 H, andR.sub.3 and R.sub.6, which may be identical to or different from each other, are each hydrogen, lower alkyl, hydroxyl, lower alkoxy, acyloxy, halogen, nitro, --SO.sub.3 H, hydroxycarbonyl-methoxy, .beta.-hydroxy-ethoxy or .beta.-amino-ethoxy,Or a salt thereof; and a method of using the same as antiallergics.

Abstract: Pyridines of the formula I ##STR1## wherein R.sub.1 is free hydroxyl, lower alkoxy, cycloalkoxy, amino-lower alkoxy or lower alkoxy-lower alkoxy, free amino, hydroxyamino, lower alkyleneamino, oxa-, aza- or thia-lower alkyleneamino or mono- or di-lower alkylamino, R.sub.2 is oxygen or sulphur, R.sub.3 and R.sub.4 are each alkoxy, free amino, mono- or di-lower alkylamino, lower alkyleneamino, oxa-, aza- or thia-lower alkyleneamino, halogen or free hydroxyl, and either R.sub.3 or R.sub.4 can be hydrogen, and alk is an alkyl group with 3-10 carbon atoms, and their N-oxides, and salts are useful as dopamine-.beta.-hydroxylase inhibitors.

Abstract: A method and composition for treatment of bacterial and fungus infections of the skin such as acne and athlete's foot is provided wherein an aqueous solution of a water soluble fluoride and a surface active agent is applied to a skin area affected.

Abstract: A medicinal preparation for treating parodontosis comprises an active principle ingredient, viz., the sodium salt of o-carboxybenzoylferrocene, combined with a pharmaceutical filler for tablets.The proposed method of treating parodontosis comprises oral administration of tablets, each, containing from 0.1 to 0.3 g of the active principle ingredient, viz., the sodium salt of o-carboxybenzoylferrocene, 2 or 3 times a day for 20 to 30 days.